A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer
一项随机、安慰剂对照、多中心、生物标志物筛选的 II 期研究，旨在评估阿普昔布联合厄洛替尼治疗晚期非小细胞肺癌患者的疗效。
期刊:Journal of Thoracic Oncology
影响因子:20.8
doi:10.1097/JTO.0000000000000082
Gitlitz, Barbara J; Bernstein, Eric; Santos, Edgardo S; Otterson, Greg A; Milne, Ginger; Syto, Mary; Burrows, Francis; Zaknoen, Sara
